Tilray Brands deepens its commitment to Europe's regulated medical cannabis sector with the launch of Tilray Medical Italia, a strategic venture with local partner Molteni Farmaceutici. The move comes as the company seeks to stabilize its growth narrative amid significant stock market volatility.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.
Gulfport Energy (NYSE: GPOR) shares have surged roughly 200% over three years, yet a deep dive reveals conflicting signals. While a cash flow model suggests significant undervaluation, its price-to-sales ratio tells a more cautious tale, leaving investors to weigh the metrics against a volatile energy backdrop.
Chemical and ammunition manufacturer Olin Corporation reported fourth-quarter results that missed internal forecasts, pressured by plant disruptions, supply issues, and a sharp year-end drop in chlorine demand. Executives emphasized cash preservation and cost control while navigating what they term an extended market downturn.
As FactSet's stock price fell 45% over the past year, investment firm McDonald Capital Investors made a significant $24 million purchase, underscoring a long-term conviction in the financial data provider's resilient, high-margin subscription business.
Novo Nordisk's newly launched oral GLP-1 drug, amycretin, has seen explosive initial demand in the U.S., potentially setting the stage for a significant financial turnaround and stock rally after a challenging previous year.
Shares of Spanish dermatology specialist Almirall (BME:ALM) present a conundrum for investors. While recent trading has been volatile, a key valuation model suggests the stock is trading at a 7.8% discount to its estimated fair value. We examine the bullish case built on its pipeline, the risks it faces, and what the significant gap between its current and forward P/E ratios might signal.
As Tilray Brands' stock languishes near multi-year lows, a deep dive into its valuation metrics suggests a significant discount. But with the cannabis sector facing headwinds, is this a genuine opportunity for investors, or a sign of deeper troubles?
Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
Defense contractor L3Harris Technologies has been awarded a U.S. Navy contract to advance the Marine Corps' precision-strike capabilities with its long-range Red Wolf missile system, designed to counter maritime threats in the Pacific.
Dover Corporation (DOV), the diversified industrial manufacturer, continues to attract heavy institutional investment, driving a remarkable long-term share price appreciation. Strong quarterly earnings and bullish guidance underscore the fundamental strength behind the sustained Big Money inflows.
The Trump administration has escalated pressure on Cuba by declaring a national emergency and threatening punitive tariffs on countries supplying it with oil, while simultaneously finalizing a reciprocal trade agreement with Guatemala aimed at bolstering Western Hemisphere supply chains.
Chevron reported robust fourth-quarter results, emphasizing record global production, major project startups, and increased shareholder returns. Executives detailed progress in the Permian Basin, Gulf of Mexico, and international ventures while outlining a confident outlook for 2026.
Quantum computing firm IonQ has moved to acquire SkyWater Technology, Skyloom Global, and Seed Innovations, aiming to create a comprehensive, end-to-end platform that controls hardware, networking, and software. This vertical integration strategy targets government and enterprise clients seeking secure, full-stack quantum solutions.
Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
